Navigation Links
Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
Date:11/12/2007

- Data presented at American College of Rheumatology Annual Congress -

BOSTON, Nov. 12 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of three post-hoc analyses from two Phase III pivotal trials that showed ORENCIA(R) (abatacept) improved daily activity participation, such as work or household chores, physical and social-role independence and sleep quality in adult rheumatoid arthritis (RA) patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate (MTX) or tumor necrosis factor (TNF) antagonists.

These data are from post-hoc analyses of two Phase III pivotal trials investigating ORENCIA: AIM (Abatacept in Inadequate responders to Methotrexate) and ATTAIN (Abatacept Trial in Treatment of Anti-TNF Inadequate Responders).

"The chronic nature of RA can have a significant impact on a person's health-related quality of life, including independence, ability to perform daily activities and sleep quality," said George Wells, M.Sc., Ph.D., Professor of the Department of Epidemiology and Community Medicine, University of Ottawa.

About the Data

Poster presentations of these analyses of the AIM (n=433 for ORENCIA plus MTX; n=219 for placebo plus MTX) and ATTAIN (n=258 for ORENCIA plus DMARDs; n=133 for placebo plus DMARDs) studies evaluating health-related quality of life improvement in daily activity participation, independence and sleep quality in RA patients treated with ORENCIA(R) (abatacept) were presented last week at the ACR Annual Scientific Meeting in Boston, MA.

An analysis of the AIM and ATTAIN studies presented by Li, et al, looked at RA patients' ability to particip
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
2. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
3. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
4. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
5. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
11. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... A new analysis and infographic released ... Hepatitis C medications could range from hundreds of millions of ... Hepatitis C receive treatment through state programs. The analysis, which ... on public programs, comes at a time when state and ... Gilead Sciences, Harvoni and Sovaldi. ...
(Date:6/30/2015)...  Inari Medical, Inc. announced today that it has ... The financing was led by members of the board ... Venture Partners.  The round also included participation by several ... pleased to complete this financing with the support of ... who joined in February 2015 as President and Chief ...
(Date:6/30/2015)... 30, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical Company focused on the development of oral drug ... been screened in the Company,s Phase IIb trial of ... will be performed under the active Investigational New Drug ... Drug Administration (FDA). The Phase IIb study ...
Breaking Medicine Technology:New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 2New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 3New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 4Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 2Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 3
... Mass.--(BUSINESS WIRE)--Jul 9, 2007 - Pro-Pharmaceuticals,Inc. (Amex: ... updated the progress of its Phase II,clinical ... cancer patients who are unable to tolerate ... trial for first-line,treatment of biliary cancer patients. ...
... Late-breaking Phase III,clinical trial data presented today ... Haemostasis (ISTH) Congress demonstrate,that once-daily rivaroxaban achieved ... (VTE) in patients undergoing,knee replacement surgery in ... of care. Patients in the RECORD3,(REgulation of ...
Cached Medicine Technology:Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 2Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 3Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 4Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 5Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5
(Date:6/30/2015)... FL (PRWEB) , ... June 30, 2015 , ... According ... doubled from 2007 to 2013 while heroin-related deaths more than tripled in the same ... threat (1). Novus Medical Detox Center , a leading Florida-based drug treatment facility, ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... According to ... received a $3.1 million grant to study how sensory stimuli can be used to ... emphasis on improving care for children with autism, will compare patient experience in a ...
(Date:6/30/2015)... ... June 30, 2015 , ... Lakeview Health, a drug and ... size of its medical staff to further enhance its ability to treat addiction ... practitioners and physician assistants -- now totals 17, compared to 7 in 2013, ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... pending in a federal multidistrict litigation now underway in the U.S. District Court, ... monthly Status Conference. According to the Court’s calendar, that conference has now been ...
(Date:6/30/2015)... ... 30, 2015 , ... Dr. Sammy Masri of Masri Sports Medicine &Wellness, NJ ... the diagnosis and treatment of non-surgical sports and other musculoskeletal injuries for both adults ... athletics and use exercise to stay healthy and active. Dr. Masri seeks to provide ...
Breaking Medicine News(10 mins):Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 2Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 4Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 5
... Researchers have discovered that some women carry a genetic ... respond to ovarian stimulating hormones during fertility treatment. The ... devising personalised fertility treatments that could bypass the problem ... told the 26th annual meeting of the European Society ...
... ... based laboratory equipment repair and instrument calibration services company, has been formally approved ... lab., , ... (PRWEB) June 29, 2010 -- Beginning in 2009, the AL-TAR Quality Department ...
... Want to lose ... weight off permanently and enjoy top physical fitness levels? See what Brilliance Weight Loss has to ... (PRWEB) June 29, ... and its customer base, as it continues to gain success with showing people how to ...
... Azmacort and ... an equivalent medication. Many have chosen to write into the People,s Medicine Community to express ... Learn more about the FDA,s decision and connect with other individuals through this special report. ... Westlake Village, CA (PRWEB) ...
... By Randy Dotinga HealthDay Reporter , MONDAY, June ... who take the cholesterol-lowering drugs known as statins are a ... But don,t demand that your doctor prescribe a statin ... for you just yet. The findings aren,t firm enough ...
... immune cell known to cause chronic inflammation in autoimmune ... low back pain associated with herniated discs, according to ... finding implicates the cytokine molecule interleukin-17, and supports the ... role in disc disease, says William J. Richardson, MD, ...
Cached Medicine News:Health News:Study finds why some women are sub-fertile with a poor response to ovarian stimulating hormones 2Health News:Study finds why some women are sub-fertile with a poor response to ovarian stimulating hormones 3Health News:AL-TAR Services, Inc. Laboratory Is Now Accredited For ACLASS Standards 2Health News:Brilliance Weight Loss Takes Dieters Beyond Trendy Low Fat Diets 2Health News:Impact of Azmacort Withdrawal Brought to Light in Medicine Community 2Health News:Impact of Azmacort Withdrawal Brought to Light in Medicine Community 3Health News:Impact of Azmacort Withdrawal Brought to Light in Medicine Community 4Health News:Impact of Azmacort Withdrawal Brought to Light in Medicine Community 5Health News:Statins May Lower Rates of Prostate Cancer Recurrence 2Health News:Surprising find may yield new avenue of treatment for painful herniated discs 2
... Stainless steel spiral reinforced. X-ray opaque . Low ... Flange: The flange can be adjusted along the ... cervical soft tissue. The lock ring is turned ... the shaft. Maximum Patient Comfort: The tube is ...
... Per-fit™ tubes are a dual ... of the disposable inner cannula ... provided in the procedural tray. ... tubes are available separately. Per-fit™ ...
Manufactured form the same soft siliconized PVC as all Portex® Blue Line® tracheostomy tubes....
Thermosensitivity of material allows tube to conform to patients anatomy for maximum patient comfort....
Medicine Products: